4.4 Article

Clinical Characteristics and Outcomes of Intracerebral Hemorrhage in Very Elderly

Journal

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
Volume 27, Issue 1, Pages 97-102

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jstrokecerebrovasdis.2017.08.006

Keywords

Intracerebral hemorrhage; elderly; outcomes; cerebral amyloid angiopathy

Funding

  1. Japan Agency for Medical Research and Development [15ek0210025h0002]
  2. Grants-in-Aid for Scientific Research [17H04308] Funding Source: KAKEN

Ask authors/readers for more resources

Background: Intracerebral hemorrhage (ICH) incidences increase with age. Patients of advanced age may have limitations during acute care and recovery. We investigated baseline characteristics, hematoma features, and outcomes of very elderly ICH patients (>= 80 years old) and compared them with those of younger ICH patients (<80 years old). Methods: We studied 377 patients (122 women; 69 +/- 11 years old) admitted within 24 hours of ICH onset. Outcome measures included hematoma volumes, National Institutes of Health Stroke Scale scores on admission, and vital and functional prognoses at 30 days. Results: After adjustments for sex, very elderly patients had a higher subcortical hematoma prevalence (odds ratio [OR], 2.62; 95% confidence interval [CI], 1.39-4.86]. On multivariate analyses, very elderly patients had larger hematoma volumes (OR, 1.33; 95% CI, 1.01-1.75, per 10-mL increase). After adjustments for risk factors and comorbidities, modified Rankin scale scores of 0-2 in very elderly patients occurred less often (OR, .34; 95% CI, .14-.82), and those with scores of 5-6 occurred more often (OR, 3.01; 95% CI, 1.09-8.54). Conclusions: Hematomas were relatively large and often found in the subcortex in very elderly ICH patients. Outcomes of very elderly ICH patients were relatively poor.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Neurosciences

Educational Campaigns at Point of Purchase in Rural Supermarkets Improve Stroke Knowledge

Yasuteru Inoue, Shoji Honda, Masaki Watanabe, Yukio Ando

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2015)

Article Neurosciences

Educational Campaigns at Point of Purchase in Rural Supermarkets Improve Stroke Knowledge

Yasuteru Inoue, Shoji Honda, Masaki Watanabe, Yukio Ando

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2015)

Article Neurosciences

Clinical Characteristics and Outcomes of Intracerebral Hemorrhage in Very Elderly

Yasuteru Inoue, Fumio Miyashita, Kazuo Minematsu, Kazunori Toyoda

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2018)

Article Neurosciences

A 23-Year-Old Woman with Sudden-Onset Blindness of the Right Eye

Yosuke Takeuchi, Keiichi Nakahara, Makoto Nakajima, Yasuteru Inoue, Riyo Matsumura, Munekage Yamaguchi, Hidetaka Katabuchi, Yukio Ando

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2019)

Review Biochemistry & Molecular Biology

Current Management and Therapeutic Strategies for Cerebral Amyloid Angiopathy

Yasuteru Inoue, Yukio Ando, Yohei Misumi, Mitsuharu Ueda

Summary: Cerebral amyloid angiopathy (CAA) is characterized by the accumulation of amyloid beta (Aβ) in brain vessels, leading to vessel fragility, hemorrhages, and neurological symptoms. The pathogenesis of CAA is not fully understood, but recent advances in mass spectrometric methodology have identified potential key molecules associated with CAA. Understanding the interactions between cerebrovascular Aβ deposits and these molecules may lead to the development of effective CAA therapeutics.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Biochemistry & Molecular Biology

α-Enolase reduces cerebrovascular Aβ deposits by protecting Aβ amyloid formation

Yasuteru Inoue, Masayoshi Tasaki, Teruaki Masuda, Yohei Misumi, Toshiya Nomura, Yukio Ando, Mitsuharu Ueda

Summary: In this study, the researchers found that α-enolase (ENO1) can interact with amyloid beta (Aβ) and inhibit its fibril formation. They also demonstrated that ENO1 can disrupt Aβ fibrils and weaken their cytotoxic effects by degrading Aβ peptides. Additionally, infusion of ENO1 into mouse brains reduced cerebrovascular Aβ deposits and improved cognitive impairment. These findings suggest that ENO1 may be a therapeutic target in cerebral amyloid angiopathy (CAA).

CELLULAR AND MOLECULAR LIFE SCIENCES (2022)

No Data Available